Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score
Psychiatric Times
JUNE 13, 2025
VMAT2 inhibitors, approved in 2017, represent a significant advancement in the treatment of TD, offering evidence-based options for managing symptoms. The AIMS exam is essential for monitoring TD, but individual experiences and functional impacts vary, requiring personalized treatment approaches.
Let's personalize your content